Rate of Pathogenic Germline Variants in Patients With Lung Cancer
JCO Precision Oncology · 2023-09 · (7)
DOI: 10.1200/po.23.00190 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Precision Oncology, 2023-09. Verfasst von Steven Sorscher und 12 weiteren Autor:innen. Beteiligte Einrichtung: Invitae, San Francisco, CA. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Germline genetic testing (GGT) is now recommended for all patients diagnosed with ovarian or pancreatic cancer and for a large proportion of patients based solely on a diagnosis of colorectal or breast cancer. However, GGT is not yet recommended for all patients diagnosed with lung cancer (LC), primarily because of a lack of evidence that supports a significant frequency of identifying pathogenic germline variants (PGVs) in these patients. This study characterizes GGT results in a cohort of patients with LC. METHODS We reviewed deidentified data for 7,788 patients with GGT (2015-2022). PGV frequencies were compared to a control cohort of unaffected individuals. GGT results were stratified by genomic ancestry, history of cancer, and PGV clinical actionability per current guidelines. RESULTS Of all patients with LC, 14.9% (1,161/7,788) had PGVs. The rate was similar when restricted to patients with no cancer family history (FH) or personal history (PH) of other cancers (14.3%). PGVs were significantly enriched in BRCA2, ATM, CHEK2, BRCA1, and mismatch repair genes compared with controls. Patients of European (EUR) genomic ancestry had the highest PGV rate (18%) and variants of uncertain significance were significantly higher in patients of non-EUR genomic ancestry. Of the PGVs identified, 61.3% were in DNA damage repair (DDR) genes and 95% were clinically actionable. CONCLUSION This retrospective study shows a LC diagnosis identifies patients with a significant likelihood of having a cancer-predisposing PGV across genomic ancestries. Enrichment of PGVs in DDR genes suggests that these PGVs may contribute to LC cancer predisposition. The frequency of PGVs among patients with LC did not differ significantly according to FH or PH of other cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Invitae, San Francisco, CA.
- Hematology/Oncology Division, Dana-Farber Cancer Center, Boston, MA.
- Nuclear Dynamics and Cancer Program, Cancer Epigenetics Institute, Fox Chase Cancer Center, Philadelphia, PA.
- Hematology, Oncology and Palliative Care Division, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA.
ORCID-Profile: Steven Sorscher, Brandie Heald, Sara L Bristow, Sarah M Nielsen, Alix Lacoste, Hayan Lee, Robert L Nussbaum, Renato Martins, Edward D Esplin
Zitieren
APA
Sorscher, S., LoPiccolo, J., Heald, B., Chen, E., Bristow, S. L., Michalski, S. T., Nielsen, S. M., Lacoste, A., Keyder, E., Lee, H., Nussbaum, R. L., Martins, R., & Esplin, E. D. (2023). Rate of Pathogenic Germline Variants in Patients With Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po.23.00190
Vancouver
Sorscher S, LoPiccolo J, Heald B, Chen E, Bristow SL, Michalski ST, et al. Rate of Pathogenic Germline Variants in Patients With Lung Cancer. JCO Precision Oncology. 2023. doi:10.1200/po.23.00190
BibTeX
@article{Sorscher2023,
author = {Sorscher, Steven and LoPiccolo, Jaclyn and Heald, Brandie and Chen, Elaine and Bristow, Sara L and Michalski, Scott T and Nielsen, Sarah M and Lacoste, Alix and Keyder, Emil and Lee, Hayan and Nussbaum, Robert L and Martins, Renato and Esplin, Edward D},
title = {Rate of Pathogenic Germline Variants in Patients With Lung Cancer},
journal = {JCO Precision Oncology},
year = {2023},
number = {7},
doi = {10.1200/po.23.00190}
}
EUVIMED